Neumora Therapeutics Faces Stock Price Drop Post-Q3 Report

Neumora Therapeutics shares are trading lower after the company announced its Q3 2025 financial results, highlighting significant preclinical advancements but drawing on $40 million of debt, raising concerns about cash needs.